Union Therapeutics is moving forward with its PDE4 inhibitor, orismilast, to a Phase III clinical trial for atopic dermatitis after positive Phase IIb study results. The company is exploring its potential for various inflammatory conditions.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing